Table 1 Prevalence of prostate cancer different PSA ranges for men with S3 M ≥ 10% risk of Gleason Score ≥ 7 cancer. Number of men with respective finding among 47,688 men in the STHLM3 study of which 3133 had a S3 M test >10% and a subsequent prostate biopsy
From: Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy
PSA ng/ml | Proportion of men by PSA in STHLM3 [3] % (n) | Men with high risk of PCa (S3 M > 10%) % (n) | Gleason Score (GS) n (%) | |||
|---|---|---|---|---|---|---|
3 + 3 | 3 + 4 | 4 + 3 | ≥4 + 4 | |||
0–0.9 | 21,230 (44.2) | 0 (0) | N/A | N/A | N/A | N/A |
1–1.4 | 8777 (18.3) | 100 (3.2) | 24 (3.1) | 5 (1.1) | 2 (2.0) | 0 (0) |
1.5–1.6 | 2593 (5.4) | 54 (1.7) | 17 (2.2) | 3 (0.6) | 0 (0.0) | 0 (0) |
1.7–1.9 | 2993 (6.2) | 105 (3.4) | 35 (4.5) | 10 (2.1) | 0 (0.0) | 1 (0.7) |
2.0–2.9 | 5906 (12.3) | 394 (12.6) | 96 (12.4) | 67 (14.2) | 18 (11.5) | 7 (5.0) |
3.0–3.9 | 2721 (5.7) | 817 (26.1) | 218 (28.2) | 110 (23.3) | 34 (21.7) | 25 (17.9) |
>4.0 | 3808 (7.9) | 1663 (53.0) | 382 (49.5) | 277 (58.7) | 103 (65.6) | 107 (76.4) |
Total | 47,688 (100) | 3133 (100) | 772 (100) | 472 (100) | 157 (100) | 140 (100) |